L Moreland

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. ncbi request reprint Management of rheumatoid arthritis: the historical context
    L W Moreland
    University of Alabama at Birmingham, 1717 6th Avenue South, SRC 068, Birmingham, AL 35294 7201, USA
    J Rheumatol 28:1431-52. 2001
  2. ncbi request reprint Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions
    Deborah Shatin
    Center for Health Care Policy and Evaluation, Minneapolis, MN, USA
    Pharmacoepidemiol Drug Saf 15:11-8. 2006
  3. ncbi request reprint Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options
    Anthony M Turkiewicz
    University of Alabama at Birmingham, Department of Medicine 35294 3408, USA
    Arthritis Rheum 56:1051-66. 2007
  4. ncbi request reprint Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis
    L W Moreland
    Department of Medicine, University of Alabama at Birmingham, USA
    Rheum Dis Clin North Am 24:579-91. 1998
  5. ncbi request reprint Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
    Larry W Moreland
    Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294 7201, USA
    J Rheumatol 33:854-61. 2006
  6. ncbi request reprint Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis
    Larry W Moreland
    University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama 35294 7201, USA
    Pharmacoeconomics 22:39-53. 2004
  7. ncbi request reprint Abatacept
    Larry Moreland
    Department of Medicine, University of Alabama, 1717 6th Ave South, Birmingham, Alabama 35294 7201, USA
    Nat Rev Drug Discov 5:185-6. 2006
  8. pmc Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action
    Larry W Moreland
    University of Alabama at Birmingham, Birmingham, AL, USA
    Arthritis Res Ther 5:54-67. 2003
  9. ncbi request reprint Disease modifiers: making the right therapeutic choices for our patients
    Larry W Moreland
    Department of Internal Medicine, University of Alabama, Birmingham, Alabama 35294, USA
    J Rheumatol Suppl 79:21-6. 2007
  10. ncbi request reprint Glucocorticoids and rheumatoid arthritis: back to the future?
    Larry W Moreland
    School of Medicine, University of Alabama at Birmingham, 1717 6th Avenue South, SRC 068, Birmingham, AL 35294 7201, USA
    Arthritis Rheum 46:2553-63. 2002

Research Grants

  1. CLINICAL RESEARCH TRAINING PROGRAM
    Larry Moreland; Fiscal Year: 2004
  2. Rheumatoid Arthritis Induction Trial (RAITMAT)
    Larry Moreland; Fiscal Year: 2007

Detail Information

Publications67

  1. ncbi request reprint Management of rheumatoid arthritis: the historical context
    L W Moreland
    University of Alabama at Birmingham, 1717 6th Avenue South, SRC 068, Birmingham, AL 35294 7201, USA
    J Rheumatol 28:1431-52. 2001
    ..It remains to be determined whether the future addition of more potent specific interventions in the immunoinflammatory process will be able to solve this problem without disarming host defenses against infections and tumors...
  2. ncbi request reprint Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions
    Deborah Shatin
    Center for Health Care Policy and Evaluation, Minneapolis, MN, USA
    Pharmacoepidemiol Drug Saf 15:11-8. 2006
    ..The aim of this study was to evaluate patterns and predictors of documented tuberculin skin testing in patients before and after manufacturer, federal, and academic risk communications...
  3. ncbi request reprint Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options
    Anthony M Turkiewicz
    University of Alabama at Birmingham, Department of Medicine 35294 3408, USA
    Arthritis Rheum 56:1051-66. 2007
  4. ncbi request reprint Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis
    L W Moreland
    Department of Medicine, University of Alabama at Birmingham, USA
    Rheum Dis Clin North Am 24:579-91. 1998
    ....
  5. ncbi request reprint Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
    Larry W Moreland
    Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294 7201, USA
    J Rheumatol 33:854-61. 2006
    ..To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug (DMARD) refractory rheumatoid arthritis (RA)...
  6. ncbi request reprint Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis
    Larry W Moreland
    University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama 35294 7201, USA
    Pharmacoeconomics 22:39-53. 2004
    ..This paper reviews the evidence for efficacy, safety and effectiveness of anti-TNF-alpha agents in RA...
  7. ncbi request reprint Abatacept
    Larry Moreland
    Department of Medicine, University of Alabama, 1717 6th Ave South, Birmingham, Alabama 35294 7201, USA
    Nat Rev Drug Discov 5:185-6. 2006
  8. pmc Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action
    Larry W Moreland
    University of Alabama at Birmingham, Birmingham, AL, USA
    Arthritis Res Ther 5:54-67. 2003
    ..Many of the physiological effects of exogenous HA may be a function of its molecular weight. Several physiological effects probably contribute to the mechanisms by which HA and hylans exert their clinical effects in knee OA...
  9. ncbi request reprint Disease modifiers: making the right therapeutic choices for our patients
    Larry W Moreland
    Department of Internal Medicine, University of Alabama, Birmingham, Alabama 35294, USA
    J Rheumatol Suppl 79:21-6. 2007
    ..Included here are the Audience Response System (ARS) results from the symposium, which will allow readers to compare their answers with that of the audience; this may help physicians in the decision-making process for their patients...
  10. ncbi request reprint Glucocorticoids and rheumatoid arthritis: back to the future?
    Larry W Moreland
    School of Medicine, University of Alabama at Birmingham, 1717 6th Avenue South, SRC 068, Birmingham, AL 35294 7201, USA
    Arthritis Rheum 46:2553-63. 2002
  11. ncbi request reprint Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
    Larry W Moreland
    Spain Rehabilitation Center, University of Alabama at Birmingham, 1717 6th Avenue South, Room 068, Birmingham, AL 35294 7201, USA
    Arthritis Rheum 46:1470-9. 2002
    ....
  12. ncbi request reprint Immune function in patients with rheumatoid arthritis treated with etanercept
    L W Moreland
    Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama 35294 7201, USA
    Clin Immunol 103:13-21. 2002
    ....
  13. pmc Unmet needs in rheumatoid arthritis
    Larry Moreland
    University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama, USA
    Arthritis Res Ther 7:S2-8. 2005
    ..Newer therapies, such as rituximab, that specifically target B cells have emerged as viable treatment options for patients with RA...
  14. ncbi request reprint Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis
    L W Moreland
    Arthritis Clinical Intervention Program, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1717 6th Avenue South, Room 068, Birmingham, AL 35294 7201, USA
    J Rheumatol 28:1238-44. 2001
    ..In this study, we examine safety and clinical benefit after longer term treatment with etanercept...
  15. pmc Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
    L Moreland
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Arthritis Res 3:247-52. 2001
    ..The only adverse event clearly associated with rhIL-11 administration was reaction at the injection site...
  16. ncbi request reprint Potential biologic agents for treating rheumatoid arthritis
    L W Moreland
    Arthritis Clinical Intervention Program, Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Rheum Dis Clin North Am 27:445-91. 2001
    ..Use of combinations of biologic therapies, perhaps in human patients with RA, should be of considerable interest in future trials...
  17. ncbi request reprint Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis
    L W Moreland
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AM, USA
    Isr Med Assoc J 3:686-90. 2001
    ..Infliximab is a chimeric monoclonal antibody composed of murine variable and human constant regions. In placebo-controlled trials, both agents have proven to be effective and well tolerated in RA patients...
  18. ncbi request reprint Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis
    L W Moreland
    Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 35294 7201, USA
    J Rheumatol 27:601-9. 2000
    ..To evaluate the safety, immunogenicity, pharmacokinetics, and efficacy of intravenous administration of tumor necrosis factor binding protein (TNFbp) dimer in patients with rheumatoid arthritis (RA)...
  19. ncbi request reprint Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis
    L W Moreland
    Department of Medicine, University of Alabama at Birmingham, USA
    Cleve Clin J Med 66:367-74. 1999
    ..Infliximab is approved for Crohn disease and etanercept for rheumatoid arthritis. Both show promise in treating rheumatoid arthritis, although the long-term risks and benefits of these drugs are not yet known...
  20. ncbi request reprint Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
    Mark C Genovese
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Arthritis Rheum 46:1443-50. 2002
    ..To compare the clinical and radiographic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy...
  21. ncbi request reprint Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis
    Larry W Moreland
    University of Alabama at Birmingham, Birmingham, AL, USA
    Arthritis Rheum 55:287-93. 2006
    ..To assess the long-term impact of etanercept on fatigue in patients with recent-onset (mean duration 11 months) or established (mean duration 12 years) rheumatoid arthritis (RA)...
  22. ncbi request reprint Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis
    Gim Gee Teng
    Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama, 1717 6th Ave South, Birmingham, AL 35294 7201, USA
    Expert Opin Biol Ther 5:1245-54. 2005
    ..Infusions were well-tolerated with a favourable safety profile similar to placebo and no appreciable immunogenicity. Abatacept is the first in a new class of biological response modifiers called costimulatory blockers...
  23. ncbi request reprint Swallowing difficulties from "DISH-phagia"
    Jeffrey R Curtis
    Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 510 20th Street South, Birmingham, AL 35294, USA
    J Rheumatol 31:2526-7. 2004
  24. ncbi request reprint Upcoming biologic agents for the treatment of rheumatic diseases
    Joseph C Shanahan
    Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Alabama, USA
    Curr Opin Rheumatol 15:226-36. 2003
    ..This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents...
  25. pmc Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study
    S Louis Bridges
    University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL 35294 2182, USA
    Arthritis Care Res (Hoboken) 62:624-31. 2010
    ....
  26. ncbi request reprint Genetic influences on rheumatoid arthritis in African Americans
    Laura B Hughes
    Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 35294 0007, USA
    Immunol Res 26:15-26. 2002
    ..g., tumor necrosis factor, interleukin-1), biologic markers of treatment response in Caucasians and in African Americans would be clinically useful...
  27. pmc Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis
    Jie Zhang
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL 35294, USA
    Arthritis Rheum 62:2219-26. 2010
    ..To examine the association between baseline bone mineral density (BMD) and radiographic damage at 3 years of disease duration in a longitudinal cohort of African Americans with recent-onset rheumatoid arthritis (RA)...
  28. pmc Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors
    Russell D Bradford
    Division of Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA
    Clin Infect Dis 49:924-7. 2009
    ..Although TNF-alpha inhibitors have been reported to increase the risk of other infectious diseases, to our knowledge, an association between anti-TNF-alpha drugs and herpes simplex virus encephalitis has not been previously described...
  29. ncbi request reprint Severity of joint pain and Kellgren-Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis
    Steven A Mazzuca
    Department of Medicine, Indiana University School of Medicine IUSM, Indianapolis, 46202, USA
    J Rheumatol 32:1540-6. 2005
    ....
  30. pmc Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data
    Ted R Mikuls
    Department of Medicine, University of Nebraska Medica Center and Omaha VA Medical Center, Omaha, NE 68198 3025, USA
    J Natl Med Assoc 97:1155-60. 2005
    ..To examine the prevalence of osteopenia and/or osteoporosis among African Americans with early rheumatoid arthritis (RA) and to assess the effect of using race/ethnicity-specific normative data...
  31. pmc Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis
    Paula I Burgos
    University of Alabama, Tuscaloosa, Alabama 35487, USA
    Arthritis Res Ther 12:R75. 2010
    ....
  32. ncbi request reprint Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis
    Ted R Mikuls
    Department of Medicine, Section of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Drug Saf 26:23-32. 2003
    ..Despite its potential for toxicity, infliximab remains a valuable alternative for patients with rheumatoid arthritis...
  33. pmc Genetic association of htSNPs across the major histocompatibility complex with rheumatoid arthritis in an African-American population
    R J Reynolds
    Section on Statistical Genetics, Department of Biostatistics, University of Alabama at Birmingham UAB, Birmingham, AL 35294 2182, USA
    Genes Immun 11:94-7. 2010
    ..28 in cases versus 0.27 in controls). This study points to the potential association of a SNP in the HLA-DOA gene with RA in African Americans, but also underscores the importance of replication of findings in larger patient cohorts...
  34. pmc An African ancestry-specific allele of CTLA4 confers protection against rheumatoid arthritis in African Americans
    James M Kelley
    University of Alabama at Birmingham, Birmingham, AL, USA
    PLoS Genet 5:e1000424. 2009
    ..An African ancestry-specific genetic variant of CTLA4 appears to be associated with protection from RA in African Americans. This finding may explain, in part, the relatively low prevalence of RA in black African populations...
  35. doi request reprint American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008
  36. pmc Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
    D Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati, ML 0563, Cincinnati, OH 45267 0563, USA
    Ann Rheum Dis 65:1325-9. 2006
    ..To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc)...
  37. ncbi request reprint A 2-phase screening process for patients with Wegener's granulomatosis: a pilot study
    Graciela S Alarcon
    Division of Clinical Immunology and Rheumatology, Department of Medicine, 615 MEB, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Rheumatol 30:2420-1. 2003
    ..One patient with WG was identified. A larger study is warranted...
  38. ncbi request reprint Rheumatoid arthritis: developing pharmacological therapies
    Joel D Abbott
    University of Alabama at Birmingham, Department of Medicine Division of Clinical Immunology and Rheumatology, 1717 6th Avenue South, SRC 068, Birmingham, AL 35294 7201, USA
    Expert Opin Investig Drugs 13:1007-18. 2004
    ..This article reviews evolving pharmacological therapies in RA with an emphasis on the newer approaches to treatment including inhibition of cognate signalling and T- and B-cell targets...
  39. ncbi request reprint Ultrasound detection of bone erosions in rheumatoid arthritis: a comparison to routine radiographs of the hands and feet
    Robert Lopez-Ben
    Department of Radiology, The University of Alabama at Birmingham, 619 19th St South, Birmingham, AL 35249 6830, USA
    Skeletal Radiol 33:80-4. 2004
    ..To determine if ultrasound (US) of selected joints in the hands and feet can detect more erosions than radiography and establish the presence of erosive disease in patients with rheumatoid arthritis (RA)...
  40. ncbi request reprint Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
    Joel M Kremer
    Center for Rheumatology, Albany, NY 12206, USA
    N Engl J Med 349:1907-15. 2003
    ..CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, blocking the engagement of CD28 on T cells and preventing T-cell activation. A preliminary study showed that CTLA4Ig may be effective for the treatment of rheumatoid arthritis...
  41. ncbi request reprint Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
    Joel M Kremer
    Center for Rheumatology, Albany, New York, USA
    Ann Intern Med 144:865-76. 2006
    ..The selective co-stimulation modulator abatacept demonstrated efficacy for treating rheumatoid arthritis in early clinical studies...
  42. ncbi request reprint Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
    J Rheumatol 33:2162-6. 2006
    ..To determine the mechanism of action of abatacept, we analyzed changes in the serum levels of inflammatory biomarkers in the patients enrolled in this trial...
  43. ncbi request reprint Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Ther 25:1700-21. 2003
    ....
  44. ncbi request reprint Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results
    Roy M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    J Rheumatol 30:691-6. 2003
    ..We compared the safety and efficacy of etanercept (Enbrel) in patients with RA who were > or = 65 years to those < 65 years in open-label and double-blind, randomized clinical trials...
  45. ncbi request reprint Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
    Stanley Cohen
    Department of Rheumatology, St Paul Medical Center, Dallas, Texas 75235, USA
    Arthritis Rheum 46:614-24. 2002
    ..To evaluate the efficacy and safety of anakinra in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA)...
  46. ncbi request reprint Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial
    Michael E Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 48:35-45. 2003
    ..To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor alpha antibody, in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite treatment with MTX...
  47. ncbi request reprint Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study
    Daniel E Furst
    University of California at Los Angeles Medical School, CA 90024, USA
    Arthritis Rheum 46:2020-8. 2002
    ..To assess the efficacy, safety, and optimal dose of tacrolimus monotherapy in patients with rheumatoid arthritis (RA)...
  48. ncbi request reprint Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis
    Tino Munster
    University of Erlangen, Erlangen, Germany
    Arthritis Rheum 46:1460-9. 2002
    ..In addition, we sought to ascertain whether further investigation of HCQ/HCQ-metabolite levels might lead to testing of one of these substances as a new antirheumatic drug...
  49. ncbi request reprint Rheumatoid arthritis: developing pharmacological therapies
    Richard J Misischia
    Expert Opin Investig Drugs 11:927-35. 2002
    ....
  50. ncbi request reprint Infliximab: additional safety data from an open label study
    Catherine L Daniel
    J Rheumatol 29:647-9. 2002
  51. ncbi request reprint Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug
    Steven A Mazzuca
    Indiana University School of Medicine, Indianapolis, 46202 5100, USA
    Arthritis Rheum 51:933-40. 2004
    ..To describe the methods by which remarkable levels of subject retention and adherence were achieved in a 30-month multicenter randomized placebo-controlled trial (RCT) of a disease-modifying osteoarthritis drug (DMOAD)...
  52. ncbi request reprint Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability
    Scott W Baumgartner
    Physician s Clinic of Spokane, Spokane, Washington 99204, USA
    J Rheumatol 31:1532-7. 2004
    ..To compare etanercept-induced improvement in disability of patients with recent onset of rheumatoid arthritis (RA) to that of patients with established RA...
  53. ncbi request reprint Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial
    Kenneth D Brandt
    Indiana University School of Medicine, Rheumatology Division, Indianapolis, IN 46202 5100, USA
    Arthritis Rheum 52:2015-25. 2005
    ..To confirm preclinical data suggesting that doxycycline can slow the progression of osteoarthritis (OA). The primary outcome measure was joint space narrowing (JSN) in the medial tibiofemoral compartment...
  54. ncbi request reprint Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
    Mark C Genovese
    Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA
    J Rheumatol 32:1232-42. 2005
    ..To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept...
  55. ncbi request reprint Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
    Joel M Kremer
    Center for Rheumatology, Albany, NY 12206, USA
    Arthritis Rheum 52:2263-71. 2005
    ..To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA-4Ig), a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has remained active despite methotrexate (MTX) therapy...
  56. ncbi request reprint The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept
    Lindsey A Criswell
    Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA, USA
    Arthritis Rheum 50:2750-6. 2004
    ..To examine the roles of specific genetic polymorphisms as predictors of response to treatment of early rheumatoid arthritis (RA)...
  57. doi request reprint Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
    Joel M Kremer
    Center for Rheumatology, Albany Medical College, Albany, New York 12206, USA
    Arthritis Rheum 58:953-63. 2008
    ..To evaluate the efficacy, radiographic changes, and safety of abatacept and methotrexate therapy through 2 years in a long-term extension of a previously published 1-year study...
  58. ncbi request reprint Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies
    Michael H Schiff
    Denver Arthritis Clinic, University of Colorado, Denver, Colorado 80230, USA
    Drugs Aging 23:167-78. 2006
    ....
  59. ncbi request reprint Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study
    Alyssa K Johnsen
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Rheumatol 33:659-64. 2006
    ..To assess the safety and efficacy of etanercept 50 mg administered twice weekly versus 25 mg administered twice weekly as monotherapy in patients with tumor necrosis factor-alpha (TNF-alpha) blocker-naƤve active rheumatoid arthritis (RA)...
  60. ncbi request reprint Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
    Daniel O Clegg
    Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    N Engl J Med 354:795-808. 2006
    ..The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis...
  61. pmc The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture
    Laura B Hughes
    University of Alabama at Birmingham 35294 2182, USA
    Arthritis Rheum 58:349-58. 2008
    ....
  62. ncbi request reprint Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis
    Ted R Mikuls
    University of Nebraska Medical Center, Omaha Veterans Administration Medical Center, Omaha, NE, USA
    Arthritis Rheum 54:3057-9. 2006
  63. ncbi request reprint High-resolution ultrasound for the study of target joints in rheumatoid arthritis
    Graciela S Alarcon
    Arthritis Rheum 46:1969-70; author reply 1970-1. 2002
  64. ncbi request reprint Outcome measurements in scleroderma: results from a delphi exercise
    Hashim Gazi
    Division of Rheumatology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada
    J Rheumatol 34:501-9. 2007
    ..To obtain a consensus on the minimal clinically relevant treatment effect in various scleroderma disease outcome measures to be used in future clinical trials...
  65. doi request reprint Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial
    Mario H Cardiel
    Hospital General Dr Miguel Silva, Morelia, Michoacan, Mexico
    Arthritis Rheum 58:2470-80. 2008
    ....
  66. ncbi request reprint Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores
    Christopher W Wu
    University of California at San Diego, La Jolla, CA 92037, USA
    Semin Arthritis Rheum 35:197-201. 2005
    ..To validate the ability of the American College of Rheumatology (ACR) clinical classification criteria and the ACR clinical plus radiographic classification criteria for osteoarthritis of the knee to predict articular cartilage damage...
  67. ncbi request reprint Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
    ..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms...

Research Grants2

  1. CLINICAL RESEARCH TRAINING PROGRAM
    Larry Moreland; Fiscal Year: 2004
    ..abstract_text> ..
  2. Rheumatoid Arthritis Induction Trial (RAITMAT)
    Larry Moreland; Fiscal Year: 2007
    ..This will lead to the development of the proposed Rheumatoid Arthritis Induction Trial with MTX and Anti-TNF Therapy (RAITMAT). ..